Grades, scores, and FDA catalyst signals for Oncology stocks tracked by BiotechSigns
| Ticker | Company | Score | Grade | Sector | Signals |
|---|---|---|---|---|---|
| GOSS | Gossamer Bio | 73 | B | Immunology/Oncology | — |
| NUVB | Nuvation Bio | 69 | B | Oncology | — |
| LBPH | Longboard Pharmaceuticals | 66 | B | Oncology | — |
| AGEN | Agenus Inc | 63 | C | Immuno-Oncology | — |
| SNDX | Syndax Pharmaceuticals | 63 | C | Oncology | — |
| MDNA | Medicenna Therapeutics | 61 | C | IL-4/IL-13 Oncology | — |
| KURA | Kura Oncology, Inc. | 60 | C | Oncology | — |
| INCY | Incyte Corporation | 60 | C | Oncology | — |
| HOOK | HOOKIPA Pharma | 59 | C | Oncology | — |
| CELC | Celcuity Inc | 58 | C | Oncology | — |
| HCM | HUTCHMED China | 58 | C | Oncology | — |
| NUVL | Nuvalent Inc | 57 | C | Oncology | — |
| EXEL | Exelixis Inc | 55 | C | Oncology | — |
| AURA | Aura Biosciences | 53 | C | Ocular Oncology | — |
| KRON | Kronos Bio | 53 | C | Oncology | — |
| LLY | Eli Lilly and Company | 53 | C | Diabetes/Oncology | — |
| BOLD | Bold Therapeutics | 52 | C | Oncology | — |
| CLDX | Celldex Therapeutics | 50 | C | Immuno-Oncology | — |
| CRVS | Corvus Pharmaceuticals | 49 | D | Oncology | — |
| TOI | The Oncology Institute, Inc. | 48 | D | Oncology | — |
| BGNE | BeiGene Ltd | 44 | D | Oncology | — |
| RAPT | RAPT Therapeutics | 44 | D | Oncology | — |
| DAWN | Day One Biopharmaceuticals | 42 | D | Pediatric Oncology | — |
| IMGN | ImmunoGen Inc | 42 | D | Oncology | — |
| GH | Guardant Health | 41 | D | Oncology Diagnostics | — |
Cancer drug development is the largest single segment of biotech, commanding the majority of FDA approvals and R&D spending each year. Oncology PDUFA dates drive some of the most volatile binary events in the market — approval can send a stock up 100–300% overnight, while a Complete Response Letter (CRL) can erase 60–80% of market cap in hours. The sector spans small-molecule chemotherapies, targeted therapies, immuno-oncology (checkpoint inhibitors, CAR-T), and antibody-drug conjugates (ADCs). Investors must assess tumor type, line of therapy, competitive landscape, and FDA precedent when evaluating PDUFA catalysts. Combination regimens and biomarker-driven patient selection have become dominant themes in modern oncology development.